exsulin : a company / a therapy / a goal

exsulin corporation was founded by diabetes industry professionals, is advised by global diabetes experts, and is dedicated to the development and commercialization of therapies
that reverse the fundamental cause of diabetes.

exsulin is aimed at correcting an underlying cause of diabetes – the loss of insulin producing islets – and is expected to offer Type 1 diabetes patients a path toward improving or normalizing glucose control. Type 2 diabetes will follow.
exsulin is a new peptide-based drug in Phase II clinical trials targeted at regeneration of insulin-producing islets in patients with established Type 1 Diabetes

exsulin has increasing evidence that islet regeneration from a patient’s own pancreas
can “turn back the clock” on the destruction of insulin producing islets

Mayo Clinic in Rochester, MN and McGill University Hospital Centre in Montreal Canada are currently enrolling patients in the first and only Phase II clinical trial targeted at regeneration of insulin-producing islets in patients with established Type 1 Diabetes.

To Learn More:

• Clinical Trials.gov
• Mayo Clinic
• McGill University Hospital Centre
• Juvenile Diabetes Research Foundation Type 1 Clinical Trials Connection
• 6th Annual Obesity and Diabetes Drug Development Summit - July 21, 2010 - Arlington, VA
Dr. Alexander Fleming presents Exsulin